COMP <GO>
STOK vs MRK // NET PROFIT MARGIN
Stoke Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: STOK 3
— MRK 7
▲ NET PROFIT MARGIN LEADER: MRK
LAST: $26.35 (-0.23%) • MKT CAP: $1.70B
net-margins
-3.70%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STOK VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STOK | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -6.10% | 20.70% | -26.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.64% | 3.42% | -0.78 | MRK | /fcf-yield <GO> |
| Operating Margin | -11.20% | 34.30% | -45.50 | MRK | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -3.70% | 28.10% | -31.80 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | STOK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.79 | 5.19 | +9.60 | STOK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.7 | 51.7 | +1.00 | STOK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.70B | $361.02B | -$359.32B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STOK REV | MRK REV | STOK GROSS % | MRK GROSS % | STOK FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $184.4M | $65.01B | — | 74.8% | $44.9M | $12.36B |
| FY 2024 | $36.6M | $64.17B | — | 76.3% | -$87.1M | $18.10B |
| FY 2023 | $8.8M | $60.12B | — | — | -$81.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STOK // BETA —
MRK // BETA 0.92